Improving palliative care for advanced cancer patients in underserved areas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the impact of Project ECHO on the quality of life and satisfaction of patients with advanced cancer and their caregivers in underserved regions of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. The study employs a comprehensive educational and telementoring intervention to empower local healthcare providers to deliver better palliative care. It aims to assess changes in patient-reported quality of life, symptom distress, and caregiver experiences, while also enhancing healthcare provider knowledge and competence in palliative care delivery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* PATIENT: Scheduled to receive treatment at participating primary care practice for advanced cancer
* PATIENT: 18 years or older
* PATIENT: Willing to be accessible to the research team for follow-up by telephone or in person
* PATIENT: Prognosis of at least 1 year as ascertained by the treating physician
* PATIENT: Able to read and understand English as assessed by the treating physician
* CAREGIVER: Identified or self-identified as primary caregiver of the patient
* CAREGIVER: Willing to be accessible to the research team for follow-up by telephone or in person
* CAREGIVER: 18 years or older
* CAREGIVER: Able to read and understand English as assessed by the treating physician
* ECHO PARTICIPANT: Participant must be a health care provider interested to participate in the study for 2 years and understand the protocol and provide consent
* ECHO PARTICIPANT: Able to read and understand English as assessed by principal investigator (PI)

Exclusion Criteria:

* Unable to understand and sign consent

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Sriram Yennu — M.D. Anderson Cancer Center
• Study coordinator: Sriram Yennu
• Email: syennu@mdanderson.org
• Phone: 713-792-6085

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• TR-002 (Nadofaragene Firadenovec) given by IV for adults with advanced unresectable or metastatic solid tumors and refractory metastatic pancreatic adenocarcinoma

  This Phase 1 trial tests whether weekly intravenous TR-002 is safe and what dose is best for adults with advanced unresectable or metastatic solid tumors or refractory metastatic pancreatic cancer.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT07189195

• Early advance care planning education for young adults with advanced solid tumors or high-grade brain tumors

  This project will test whether short educational tools help adolescents and young adults (diagnosed at 18–39) with advanced solid tumors or high-grade brain tumors start advance care planning earlier.

  Recruiting Mayo Clinic · Scottsdale, Arizona · NCT07174661

• Telephone coaching to help people with advanced cancer and their support person plan for end-of-life care

  This program tests whether two phone coaching sessions help people with advanced cancer and their support person have end-of-life conversations and complete advance directives.

  Recruiting at 3 sites Fred Hutchinson Cancer Center · Everett, Washington and 2 other locations · NCT07141407

• Video education to boost knowledge and interest in cancer clinical trials

  Adults in the Detroit area will watch a short educational video to see if it increases their knowledge about and interest in cancer clinical trials.

  Recruiting Barbara Ann Karmanos Cancer Institute · Detroit, Michigan · NCT06501040

• Using siltuximab to prevent severe side effects during cancer treatment

  This study is testing if the drug siltuximab can help prevent severe side effects in cancer patients who are getting immune therapy again.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06470971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.